Mitigation of AAA progression and redox modulation was also reflected in the downregulation of platelet activation, MAPK signaling, restriction of vascular inflammation via miR-181a-5p activity, and inhibition of cellular apoptosis via miR17-5p activity and STAT3 signaling. The gene discussed is STAT3; the disease is triple-A syndrome.